Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 22

1.

Metabolomics of Small Intestine Neuroendocrine Tumors and Related Hepatic Metastases.

Imperiale A, Poncet G, Addeo P, Ruhland E, Roche C, Battini S, Cicek AE, Chenard MP, Hervieu V, Goichot B, Bachellier P, Walter T, Namer IJ.

Metabolites. 2019 Dec 11;9(12). pii: E300. doi: 10.3390/metabo9120300.

2.

Neuropilin-2 contributes to tumor progression in preclinical models of small intestinal neuroendocrine tumors.

Bollard J, Patte C, Radkova K, Massoma P, Chardon L, Valantin J, Gadot N, Goddard I, Vercherat C, Hervieu V, Gouysse G, Poncet G, Scoazec JY, Walter T, Roche C.

J Pathol. 2019 Nov;249(3):343-355. doi: 10.1002/path.5321. Epub 2019 Sep 3.

PMID:
31257576
3.

Combinatorial Treatment with mTOR Inhibitors and Streptozotocin Leads to Synergistic In Vitro and In Vivo Antitumor Effects in Insulinoma Cells.

Bollard J, Patte C, Massoma P, Goddard I, Gadot N, Benslama N, Hervieu V, Ferraro-Peyret C, Cordier-Bussat M, Scoazec JY, Roche C, Walter T, Vercherat C.

Mol Cancer Ther. 2018 Jan;17(1):60-72. doi: 10.1158/1535-7163.MCT-17-0325. Epub 2017 Oct 19.

4.

mTOR inhibitors activate PERK signaling and favor viability of gastrointestinal neuroendocrine cell lines.

Freis P, Bollard J, Lebeau J, Massoma P, Fauvre J, Vercherat C, Walter T, Manié S, Roche C, Scoazec JY, Ferraro-Peyret C.

Oncotarget. 2017 Mar 28;8(13):20974-20987. doi: 10.18632/oncotarget.15469.

5.

Prediction of response to everolimus in neuroendocrine tumors: evaluation of clinical, biological and histological factors.

Benslama N, Bollard J, Vercherat C, Massoma P, Roche C, Hervieu V, Peron J, Lombard-Bohas C, Scoazec JY, Walter T.

Invest New Drugs. 2016 Oct;34(5):654-62. doi: 10.1007/s10637-016-0363-6. Epub 2016 May 26.

PMID:
27230034
6.

The axon guidance molecule semaphorin 3F is a negative regulator of tumor progression and proliferation in ileal neuroendocrine tumors.

Bollard J, Massoma P, Vercherat C, Blanc M, Lepinasse F, Gadot N, Couderc C, Poncet G, Walter T, Joly MO, Hervieu V, Scoazec JY, Roche C.

Oncotarget. 2015 Nov 3;6(34):36731-45. doi: 10.18632/oncotarget.5481.

7.

Mechanisms of local invasion in enteroendocrine tumors: identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors.

Couderc C, Bollard J, Couté Y, Massoma P, Poncet G, Lepinasse F, Hervieu V, Gadot N, Sanchez JC, Scoazec JY, Diaz JJ, Roche C.

Mol Cell Endocrinol. 2015 Jan 5;399:154-63. doi: 10.1016/j.mce.2014.09.006. Epub 2014 Sep 16.

PMID:
25224486
8.

Antitumor effect of everolimus in preclinical models of high-grade gastroenteropancreatic neuroendocrine carcinomas.

Bollard J, Couderc C, Blanc M, Poncet G, Lepinasse F, Hervieu V, Gouysse G, Ferraro-Peyret C, Benslama N, Walter T, Scoazec JY, Roche C.

Neuroendocrinology. 2013;97(4):331-40. doi: 10.1159/000347063. Epub 2013 May 22.

9.

Effects of somatostatin and octreotide on the interactions between neoplastic gastroenteropancreatic endocrine cells and endothelial cells: a comparison between in vitro and in vivo properties.

Walter T, Hommell-Fontaine J, Gouysse G, Pourreyron C, Nejjari M, Villaume K, Causeret S, Hervieu V, Poncet G, Roche C, Scoazec JY.

Neuroendocrinology. 2011;94(3):200-8. doi: 10.1159/000328134. Epub 2011 Jun 16.

PMID:
21677423
10.

Well-differentiated pancreatic islet cell carcinoma: Is there reversibility in mTOR inhibitor resistance?

Walter T, Scoazec JY, Couderc C, Forestier J, Roche C, Chayvialle JA, Lombard-Bohas C.

Acta Oncol. 2011 Jun;50(5):731-2. doi: 10.3109/0284186X.2011.562919. Epub 2011 Mar 17. No abstract available.

PMID:
21413853
11.

Targeting the PI3K/mTOR pathway in murine endocrine cell lines: in vitro and in vivo effects on tumor cell growth.

Couderc C, Poncet G, Villaume K, Blanc M, Gadot N, Walter T, Lepinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C.

Am J Pathol. 2011 Jan;178(1):336-44. doi: 10.1016/j.ajpath.2010.11.023. Epub 2010 Dec 23.

12.

The overexpression of the putative gut stem cell marker Musashi-1 induces tumorigenesis through Wnt and Notch activation.

Rezza A, Skah S, Roche C, Nadjar J, Samarut J, Plateroti M.

J Cell Sci. 2010 Oct 1;123(Pt 19):3256-65. doi: 10.1242/jcs.065284. Epub 2010 Sep 7.

13.

VEGF secretion by neuroendocrine tumor cells is inhibited by octreotide and by inhibitors of the PI3K/AKT/mTOR pathway.

Villaume K, Blanc M, Gouysse G, Walter T, Couderc C, Nejjari M, Vercherat C, Cordier-Bussat M, Roche C, Scoazec JY.

Neuroendocrinology. 2010;91(3):268-78. doi: 10.1159/000289569. Epub 2010 Apr 13.

PMID:
20389030
14.

Magnetic resonance imaging follow-up of liver growth of neuroendocrine tumors in an experimental mouse model.

Baboi L, Pilleul F, Milot L, Lartizien C, Poncet G, Roche C, Scoazec JY, Beuf O.

Magn Reson Imaging. 2010 Feb;28(2):264-72. doi: 10.1016/j.mri.2009.06.003. Epub 2009 Aug 19.

PMID:
19695818
15.

MEN1 missense mutations impair sensitization to apoptosis induced by wild-type menin in endocrine pancreatic tumor cells.

Bazzi W, Renon M, Vercherat C, Hamze Z, Lacheretz-Bernigaud A, Wang H, Blanc M, Roche C, Calender A, Chayvialle JA, Scoazec JY, Cordier-Bussat M.

Gastroenterology. 2008 Nov;135(5):1698-1709.e2. doi: 10.1053/j.gastro.2008.07.031. Epub 2008 Jul 31.

PMID:
18775714
16.

Angiogenesis and tumor progression in neuroendocrine digestive tumors.

Poncet G, Villaume K, Walter T, Pourreyron C, Theillaumas A, Lépinasse F, Hervieu V, Cordier-Bussat M, Scoazec JY, Roche C.

J Surg Res. 2009 Jun 1;154(1):68-77. doi: 10.1016/j.jss.2008.03.055. Epub 2008 Apr 29.

PMID:
18708196
17.

Relation between menin expression and NF-kappaB activity in an intestinal cell line.

Theillaumas A, Blanc M, Couderc C, Poncet G, Bazzi W, Bernard C, Cordier-Bussat M, Scoazec JY, Roche C.

Mol Cell Endocrinol. 2008 Sep 10;291(1-2):109-15. doi: 10.1016/j.mce.2008.05.019. Epub 2008 Jun 11.

PMID:
18590796
18.

In vitro and in vivo studies with [(18)F]fluorocholine on digestive tumoral cell lines and in an animal model of metastasized endocrine tumor.

Nejjari M, Kryza D, Poncet G, Roche C, Perek N, Chayvialle JA, Le Bars D, Scoazec JY, Janier M, Borson-Chazot F.

Nucl Med Biol. 2008 Jan;35(1):123-30.

PMID:
18158951
19.

The role of angiogenesis in endocrine liver metastases: an experimental study.

Pourreyron C, Poncet G, Roche C, Gouysse G, Nejjari M, Walter T, Villaume K, Jacquier MF, Bernard C, Dumortier J, Chayvialle JA, Bachelot T, Scoazec JY.

J Surg Res. 2008 Jan;144(1):64-73. Epub 2007 Jul 23.

PMID:
17643449
20.

Reduction of menin expression enhances cell proliferation and is tumorigenic in intestinal epithelial cells.

Ratineau C, Bernard C, Poncet G, Blanc M, Josso C, Fontanière S, Calender A, Chayvialle JA, Zhang CX, Roche C.

J Biol Chem. 2004 Jun 4;279(23):24477-84. Epub 2004 Mar 30.

Supplemental Content

Loading ...
Support Center